RE:RE:RE:RE:RE:RE:RE:RE:RE:New Corporate Presentation up "Explore the need for a companion diagnostic for SORT1 to determine correlation of sortilin expression with response, improve patient selection, track treatment efficacy and identify early metastases"
Is there an opportunity to commercialize a diagnostic and use it for routine metastases screening and not just use it for patient selection and responses?